From beginning of 2020 till now, it has 5 IVD enterprise announced to spin-off listing, such as BGI, Livzon Diagnostics, Lepu, Fosun Pharma & Dian Diagnostics. In general, it arose many risks, however, the direct connection with capital market of these subsidiaries will enlarge the diversified financing channels, enhance the competitiveness and realize the great-leap development.

BGI

Founded in 1999, BGI is one of the world's leading life science and genomics organizations. BGI’s mission is to use genomics to benefit mankind and to be a leader in the era of life sciences. BGI follows a genomics development model of “research, production and application”. With businesses in more than 100 countries and regions around the world, BGI has established cooperation and partnerships with thousands of different organizations across multi-disciplinary research areas including medical health, resource conservation and judicial services. At the same time, BGI provides equipment, technical support and solutions for the needs of national economies and people's livelihoods, such as precision medicine and precision health. BGI is committed to applying its genetic and technological achievements to real world settings in order to realize the dream of trans-omics for a better life.

MGI Tech Co., Ltd.

MGI Tech Co., Ltd. (referred to as MGI) is committed to building core tools and technology to lead life science through intelligent innovation. MGI focuses on R&D, production and sales of DNA sequencing instruments, reagents, and related products to support life science research, agriculture, precision medicine and healthcare. MGI is a leading producer of clinical high-throughput gene sequencers, and its multi-omics platforms include genetic sequencing, mass spectrometry, medical imaging, and laboratory automation.

Founded in 2016, MGI has more than 1000 employees, nearly half of whom are R&D personnel. MGI operates in 39 countries and regions and has established multiple research and production bases around the world. Providing real-time, comprehensive, life-long solutions, its vision is to enable effective and affordable healthcare solutions for all.

Livzon Pharmaceutical Group Inc.

Livzon Pharmaceutical Group Inc. is dedicated to the improvement of human life and health. With this goal in mind, the company's business objectives are to provide domestic first-class, world leading specialty drugs and the company aims to strategically advance toward the business development of precision medicines and the related endeavors.

Zhuhai Livzon Diagnostics Inc.

Zhuhai Livzon Diagnostics Inc. (hereinafter referred to as “Livzon Diagnostics”) was established in 1989. It is the first high-tech subsidiary of the listed company, Livzon Pharmaceutical Group (A-share and H-share listed company), who specializing in in-vitro diagnostics in research, developing, manufacturing and marketing of diagnosis products and automation equipment. Livzon Diagnostics is one of the earliest in vitro diagnostic products manufacturing enterprises in China, a national high-tech enterprise.

Livzon Diagnostics has established many technical platforms such as Enzyme-linked Immunoassay, lateral flow chromatography, Microorganisms testing, Molecular testing, Multiple-detection Immunoassay, Single-test Chemiluminescence immunoassay, Mast Cell Degranulation Test for Allergy, etc. Meanwhile, Livzon Diagnostics also has fully automatic equipment development capability. The products cover many disease areas such as infectious diseases, respiratory infection, tumor marker detection, drug concentration monitoring, autoimmunity, allergen detection, and blood safety. Therefore, Livzon Diagnostics has high market share in respiratory infections, infectious diseases, and drug concentration monitoring with market share as high as 50% -90%.

Zhuhai Livzon Diagnostics Inc.  has equipped with its industrialization base for Research and Development, Production and Office use, which covers an area of more than 23,000 square meters, construction area of more than 44,000 square meters, including 6000 square meters for Research and Development, which attracts professional elite talents from Laboratory Science, Biological engineering and many other fields. Zhuhai Livzon Diagnostics Inc. owns 5 Research and Development teams spread in 3 Research and Development centers, which located in Zhuhai, Shanghai and Suzhou city. The total Research and Development personnel accounted for nearly 20% , meanwhile the annual Research and Development investment reaches more than 10% of Sales Revenue. Beside its independent Research and Development, Zhuhai Livzon Diagnostics Inc. has established long-term successful cooperation with many first-class International Biomedical Enterprises such as Fujirebro from Japan, Siemens in Germany, and MP company (USA), which has enhanced its comprehensive service capabilities. Zhuhai Livzon Diagnostics Inc. has won the title of honor as "National High-tech Enterprises", "In vitro diagnostic Engineering Technology Research Center of Guangdong Province ", "Guangdong Provincial Enterprise Technology Center", "Innovative Enterprises of Guangdong Province " and the national "Post-doctoral Research Station". With a complete quality management system in production, Zhuhai Livzon Diagnostics Inc. has well achieved the national GMP certification, GSP certification and ISO13485/ISO9001 certification.

Lepu Medical

Established in 1999, Lepu Medical devoted itself into 4 plates of medical equipment, pharmaceutical product, medical service and new-type medical industry.

Lepu (Beijing) Diagnostics Co., Ltd.

Established in 2011, Lepu Diagnostics specialized in R&D, production & marketing on IVD reagent formulating the industrial distribution of blood diagnostic and POCT immunologic, molecular & biochemical diagnostics product as well. From 2017-2019, the company achieved the revenue of 162.63 million, 220.56 million and 269.56 million RMB with the net profits attributed to the shareholders of the parent company are respectively 36.63 million, 36.68 million and 47.36 million RMB.

Fosun Pharma

Fosun was founded in 1992. Fosun International Limited is an innovation-driven consumer group that has been listed on the main board of the Hong Kong Stock Exchange (00656.HK) since 2007, with total assets of RMB715.7 billion (c.US$102.6 billion) as of 31 December 2019 and total revenue of RMB143.0 billion (c.US$20.7 billion) in 2019. Fosun's mission is to provide high-quality products and services for families around the world in health, happiness and wealth businesses. Fosun International ranks No.371 on the 2020 Forbes Global 2000 List.

GlandPharma

A holistic objective of dispensing health through a portfolio of injectable products across various therapeutic segments and delivery systems, has helped us expand to seven manufacturing facilities in India, with a capacity of approximately 750 million units. These include four facilities with 22 production lines for finished formulations and three Active Pharmaceutical Ingredient (API) facilities. Our products are produced at world-class manufacturing facilities and conform to global compliance, regulatory and quality specifications.

We are present in sterile injectables, oncology and ophthalmic segments, and focus on complex injectables including NCE-1s, First-to-File products and 505(b)(2) filings. Our products are currently delivered via liquid vials, lyophilized vials, pre-filled syringes, ampoules, bags and drops; and efforts are underway to augment additional manufacturing capabilities in complex injectables such as peptides, long-acting injectables, suspensions and hormonal products. We are also in the process of including new delivery systems such as pens and cartridges into our product portfolio.

Our ethos at work is to consistently focus on meeting diverse injectable needs with high-quality products at attractive price points. On this strong plinth of looking ahead, we have successfully and repeatedly harnessed our R&D expertise in synthesizing complex molecules to produce complex injectables. Enabling us to develop niche products for diverse markets worldwide.

DiAn Diagnostics

Established in 2001, DiAn Diagnostics is an independent third-party medical diagnostic services institute embracing the medical diagnostic service for product marketing, judicial expertise, healthcare management, cold-chain logistics, R&D, CRO as well as the bio bank.

Hangzhou Calibra Precision Diagnostics Technology Co., Ltd.

Setting up in 2016, Hangzhou Calibra Precision Diagnostics Technology Co., Ltd. Is a high-tech enterprise focusing on R&D for multi-omics biomarker spectrum, clinical transformation and application which has already completed over 200 methodology of independent research and clinical verification. Surrounding several direction of applications such as in-vitro diagnostic, clinical research, Metabonomics, environment and clinical toxicology, the company supplies the integrated clinical method of Product+Service+Management solution.

The achieved revenue for 2018 and Jan.-Sep. in 2019 was 179.7 million and 219.7 million with 2.94 million and 2.50 million net profit.

A-share spin-off listing set off a crazy trend recently. According to Securities Daily, till Aug. 13, exceeding 40 listed companies planned to spin-off listing, over tens of them are biomedical enterprise aiming for Science & Technology Innovation Board and GEM.